Determination of desmoglein 1 and 3 antibody levels by ELISA in patients with pemphigus after treatment with rituximab
Phase 3
- Conditions
- Pemphigus.Pemphigus
- Registration Number
- IRCT20220117053747N1
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Patients with pemphigus vulgaris
Patients with pemphigus follicia
Active pemphigus disease
Patients being treated for pemphigus
Patients resistant to previous treatments
Patients resistant to previous treatments
Exclusion Criteria
Having active infections
Cardiac arrhythmia or cardiac conduction disorders
Ejection fraction below 40%
Evidence of other autoimmune diseases
History of receiving ritoximab in the past
Pregnancy and breastfeeding
Patients with a history of allergies and anaphylactic shock
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pemphigus disease severity. Timepoint: Will be evaluated 1, 3 and 6 months after the intervention. Method of measurement: Pemphigus Disease Area Index.;Desmoglein 1 and 3 antibody level. Timepoint: Will be evaluated before intervention and 1, 3 and 6 months after the intervention. Method of measurement: Elisa.
- Secondary Outcome Measures
Name Time Method